Avanos Medical, Inc. Stock News

Avanos Medical, Inc. ( AVNS ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Jason Pickett - Vice President of Tax & Treasurer David Pacitti - CEO & Director Scott Galovan - CFO & Senior VP Conference Call Participants Daniel Stauder - Citizens JMP Securities, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Avanos Thir...

Delivered double-digit growth in Specialty Nutrition Systems segment Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment Raising and narrowing top-line guidance and adjusted EPS guidance for the full year ALPHARETTA, Ga. , Nov. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2025 financial r...

ALPHARETTA, Ga. , Oct. 27, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2025 on Wed.

ANN ARBOR, Mich. , Oct. 23, 2025 /PRNewswire/ -- WRS Group, LLC (WRS), a privately held company based in Ann Arbor, Michigan, announced today that it has entered into a definitive agreement with Avanos Medical, Inc. (NYSE: AVNS) to acquire substantially all assets and rights related to Avanos' US Game Ready® orthopedic rental business.

Avanos Medical is deeply undervalued, with strong international expansion, aggressive M&A strategy, and a new CFO poised to drive inorganic growth. AVNS operates in high-growth markets, maintains a solid balance sheet with low debt, and trades at a significant discount to sector peers on earnings and book value. Ongoing transformation, divestitures, and stock repurchases are expected to enhance...

ALPHARETTA, Ga. , Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas.

Avanos Medical, Inc. appears deeply undervalued after years of restructuring, with a potential stabilization in sales and earnings projected for 2025. Recent tariff impacts and lowered guidance seem fully priced in, setting the stage for upside surprises and a share price rally into 2026. Insider buying and improving technical indicators suggest a sea change for investor confidence could be next.

Avanos Medical, Inc. (NYSE:AVNS ) Q2 2025 Earnings Conference Call August 5, 2025 9:00 AM ET Company Participants David C. Pacitti - Chief Executive Officer Jason M.